EU routes to market for drugs and biologics
How EU medicines reach the market: the centralised Union route, national authorisation, mutual recognition and decentralised procedures, with their timelines and evidence.
5 posts
How EU medicines reach the market: the centralised Union route, national authorisation, mutual recognition and decentralised procedures, with their timelines and evidence.
How the NDA, 505(b)(2), ANDA and BLA routes work under 21 CFR Parts 314 and 601 and what evidence each requires.
How Article 5(5) of the IVDR allows a health institution to make and use its own in vitro diagnostic, and the nine conditions attached.
How device class under Regulation (EU) 2017/745 sets the conformity assessment route, with the Annex IX, X and XI procedures and transitional deadlines.
How FDA premarket routes divide between 510(k), De Novo and PMA, with the criteria, contents and review timeframes set by 21 CFR parts 807 and 814.